ArticleJournal of orthopaedic translation2026
Single-cell and spatial transcriptomics characterisation of RSPO2
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intervertebral disc degeneration (IVDD) is a common cause of chronic low back pain, imposing a significant economic and physiological burden on individuals and society worldwide. Although dysregulation of the WNT/β-catenin pathway is considered an important factor contributing to the dysfunction of nucleus pulposus (NP) cells and degradation of the extracellular matrix, the mechanisms by which specific subgroups of NP cells are activated and the maintenance of excessive activation of specific pathways remain unclear. Methods: We combined single-cell RNA sequencing and spatial transcriptomics with human disc specimens, a rat tail-compression model using static 1.5 MPa loading, an independent rat needle-puncture time-course model, primary NP-cell experiments using continuous static hydrostatic pressure (0.2 MPa for 24 h), WNT-pathway perturbation, molecular docking and dynamics, and targeted siRNA. Computational analyses were interpreted at the cell/spot level, whereas animal-level inference used the stated biological replicates. Results: Single-cell transcriptomics identified R-spondin 2 (RSPO2) as a selective marker of a homeostatic NP-resident Cluster 1 compartment whose proportion contracted after mechanical injury, while RSPO2-related WNT/FN1-CD44 signalling scores increased across expanded degenerative effector populations. Human panels were used as representative cross-sectional comparisons without inferential between-grade testing. In NP cells, 0.2 MPa pressure and exogenous RSPO2 enhanced WNT/β-catenin, FN1-CD44, matrix-catabolic and apoptotic responses; IWR-1 and DKK1 attenuated these changes. Molecular docking, 100-ns dynamics and a forward co-immunoprecipitation were consistent with an RSPO2-LGR4 association. RSPO2 worsened degeneration in the 1.5 MPa rat compression model, whereas combined IWR-1 treatment was protective. Spatial transcriptomics provided descriptive maps across the needle-puncture time course, and machine-learning models showed internal spot-level discrimination of the prespecified RSPO2-associated labels. Conclusion: RSPO2 is a candidate regulator, rather than only a marker, of an IVDD-associated NP state. The perturbation data support an RSPO2-associated WNT amplification program coupled to FN1-CD44/MMP3 activation, but the proposed ordering remains provisional pending independent-siRNA and rescue validation. The translational potential of this article: This study identifies an RSPO2-associated NP state and a candidate WNT/FN1-CD44 programme linked to IVDD. The findings provide a testable basis for future WNT-directed intervention studies while recognising the limits of acute rat models and cross-species data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.